{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:04:13Z","timestamp":1776179053590,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"am","delay-in-days":303,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJS2123"],"award-info":[{"award-number":["JPMJS2123"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.cellsig.2022.110537","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T21:30:47Z","timestamp":1669411847000},"page":"110537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The indispensable role of the RNA helicase DDX5 in tumorigenesis induced by the myeloproliferative neoplasm-associated JAK2V617F mutant"],"prefix":"10.1016","volume":"102","author":[{"given":"Kengo","family":"Takeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Funakoshi-Tago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellsig.2022.110537_bb0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0092-8674(93)90414-L","article-title":"JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin","volume":"74","author":"Witthuhn","year":"1993","journal-title":"Cell."},{"key":"10.1016\/j.cellsig.2022.110537_bb0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0168-9525(00)89000-9","article-title":"Jaks and stats in signaling by the cytokine receptor superfamily","volume":"11","author":"Ihle","year":"1995","journal-title":"Trends Genet. TIG"},{"key":"10.1016\/j.cellsig.2022.110537_bb0015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellsig.2022.110537_bb0020","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature."},{"key":"10.1016\/j.cellsig.2022.110537_bb0025","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation","volume":"102","author":"Lu","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cellsig.2022.110537_bb0030","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1128\/MCB.01447-07","article-title":"Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity","volume":"28","author":"Funakoshi-Tago","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.cellsig.2022.110537_bb0035","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1074\/jbc.M109.040733","article-title":"STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant","volume":"285","author":"Funakoshi-Tago","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellsig.2022.110537_bb0040","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1074\/jbc.M116.749465","article-title":"Three tyrosine residues in the erythropoietin receptor are essential for Janus kinase 2 V617F mutant-induced tumorigenesis","volume":"292","author":"Ueda","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellsig.2022.110537_bb0045","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1365-2141.2010.08249.x","article-title":"JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation","volume":"150","author":"Oku","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cellsig.2022.110537_bb0050","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.cellsig.2011.01.009","article-title":"Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation","volume":"23","author":"Kamishimoto","year":"2011","journal-title":"Cell. Signal."},{"key":"10.1016\/j.cellsig.2022.110537_bb0055","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell."},{"key":"10.1016\/j.cellsig.2022.110537_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054826","article-title":"mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms","volume":"8","author":"Bogani","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cellsig.2022.110537_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135463","article-title":"Microarray and proteomic analyses of myeloproliferative neoplasms with a highlight on the mTOR signaling pathway","volume":"10","author":"\u010coki\u0107","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cellsig.2022.110537_bb0070","doi-asserted-by":"crossref","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-06-2210","article-title":"Characterization of murine JAK2V617F-positive myeloproliferative disease","volume":"66","author":"Bumm","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2022.110537_bb0075","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2022.110537_bb0080","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-319-91439-8_6","article-title":"Ruxolitinib","volume":"212","author":"Ajayi","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.cellsig.2022.110537_bb0085","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1097-2765(01)00329-X","article-title":"DExD\/H box RNA helicases: from generic motors to specific dissociation functions","volume":"8","author":"Tanner","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cellsig.2022.110537_bb0090","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1128\/MCB.22.15.5443-5450.2002","article-title":"Liu, p68 RNA helicase is an essential human splicing factor that acts at the U1 snRNA-5\u2032 splice site duplex","volume":"22","author":"ZR.","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.cellsig.2022.110537_bb0095","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/cas.12755","article-title":"DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating \u03b2-catenin signaling pathway","volume":"106","author":"Wang","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.cellsig.2022.110537_bb0100","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/sj.emboj.7600550","article-title":"The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor","volume":"24","author":"Bates","year":"2005","journal-title":"EMBO J."},{"key":"10.1016\/j.cellsig.2022.110537_bb0105","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/onc.2013.561","article-title":"Arf tumor suppressor disrupts the oncogenic positive feedback loop including c-Myc and DDX5","volume":"34","author":"Tago","year":"2015","journal-title":"Oncogene."},{"key":"10.1016\/j.cellsig.2022.110537_bb0110","doi-asserted-by":"crossref","first-page":"7734","DOI":"10.1038\/sj.onc.1204976","article-title":"Overexpression and poly-ubiquitylation of the DEAD-box RNA helicase p68 in colorectal tumours","volume":"20","author":"Causevic","year":"2001","journal-title":"Oncogene."},{"key":"10.1016\/j.cellsig.2022.110537_bb0115","doi-asserted-by":"crossref","first-page":"7938","DOI":"10.1158\/0008-5472.CAN-08-0932","article-title":"The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer","volume":"68","author":"Clark","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2022.110537_bb0120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000217961","article-title":"Expression of the double-stranded RNA-dependent protein kinase (p68) in human breast tissues","volume":"17","author":"Haines","year":"1996","journal-title":"Tumour Biol."},{"key":"10.1016\/j.cellsig.2022.110537_bb0125","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1093\/nar\/24.19.3739","article-title":"p72: a human nuclear DEAD box protein highly related to p68","volume":"24","author":"Lamm","year":"1996","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cellsig.2022.110537_bb0130","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.celrep.2014.05.010","article-title":"RNA helicases DDX5 and DDX17 dynamically orchestrate transcription, miRNA, and splicing programs in cell differentiation","volume":"7","author":"Dardenne","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.cellsig.2022.110537_bb0135","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.devcel.2006.08.003","article-title":"The RNA helicases p68\/p72 and the noncoding RNA SRA are coregulators of MyoD and skeletal muscle differentiation","volume":"11","author":"Caretti","year":"2006","journal-title":"Dev. Cell"},{"key":"10.1016\/j.cellsig.2022.110537_bb0140","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.leu.2404081","article-title":"JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders","volume":"20","author":"Quentmeier","year":"2006","journal-title":"Leukemia."},{"key":"10.1016\/j.cellsig.2022.110537_bb0145","article-title":"Identification of DDX5 as an indispensable activator of the glucocorticoid receptor in adipocyte differentiation","author":"Hokimoto","year":"2022","journal-title":"FEBS J. Adv. Online Publ."},{"key":"10.1016\/j.cellsig.2022.110537_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113666","article-title":"Methotrexate significantly induces apoptosis by inhibiting STAT3 activation in NPM-ALK-positive ALCL cells","volume":"170","author":"Uchihara","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cellsig.2022.110537_bb0155","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aat3834","article-title":"Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis","volume":"4","author":"Tvorogov","year":"2018","journal-title":"Sci. Adv."},{"key":"10.1016\/j.cellsig.2022.110537_bb0160","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","article-title":"The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors","volume":"117","author":"Nelson","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.cellsig.2022.110537_bb0165","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-020-2760-4","article-title":"Structural basis for the action of the drug trametinib at KSR-bound MEK","volume":"588","author":"Khan","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.cellsig.2022.110537_bb0170","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s41419-018-0943-9","article-title":"Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-\u03baB directly regulates PUMA-dependent apoptosis","volume":"9","author":"Sun","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cellsig.2022.110537_bb0175","doi-asserted-by":"crossref","first-page":"ra37","DOI":"10.1126\/scisignal.2002618","article-title":"An ATP-site on-off switch that restricts phosphatase accessibility of Akt","volume":"5","author":"Lin","year":"2012","journal-title":"Sci. Signal."},{"key":"10.1016\/j.cellsig.2022.110537_bb0180","doi-asserted-by":"crossref","first-page":"27251","DOI":"10.1074\/jbc.M501376200","article-title":"Janus kinases affect thrombopoietin receptor cell surface localization and stability","volume":"280","author":"Royer","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellsig.2022.110537_bb0185","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2007-07-102186","article-title":"The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes","volume":"111","author":"Wernig","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.cellsig.2022.110537_bb0190","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1615\/CritRevOncog.v16.i1-2.90","article-title":"C\/EBP\u03b1 dysregulation in AML and ALL","volume":"16","author":"Paz-Priel","year":"2011","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.cellsig.2022.110537_bb0195","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","article-title":"The broken cycle: E2F dysfunction in cancer","volume":"19","author":"Kent","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellsig.2022.110537_bb0200","first-page":"3475","article-title":"Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1","volume":"12","author":"Schulze","year":"1994","journal-title":"Oncogene."},{"key":"10.1016\/j.cellsig.2022.110537_bb0205","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/emboj\/18.5.1367","article-title":"Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells","volume":"18","author":"Matsumura","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.cellsig.2022.110537_bb0210","article-title":"Induction of DEAD box helicase 5 in early adipogenesis is regulated by ten-eleven translocation 2","volume":"1865","author":"Cho","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.cellsig.2022.110537_bb0215","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2022.110537_bb0220","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1136\/jcp.2010.080218","article-title":"Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms","volume":"63","author":"Chim","year":"2010","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.cellsig.2022.110537_bb0225","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ymthe.2019.12.013","article-title":"Long noncoding RNA NHEG1 drives \u03b2-catenin transactivation and neuroblastoma progression through interacting with DDX5","volume":"28","author":"Zhao","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cellsig.2022.110537_bb0230","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-018-0656-7","article-title":"The lncRNA NEAT1 activates Wnt\/\u03b2-catenin signaling and promotes colorectal cancer progression via interacting with DDX5","volume":"11","author":"Zhang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cellsig.2022.110537_bb0235","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/jcmm.14038","article-title":"O-GlcNAcylation promotes colorectal cancer progression by regulating protein stability and potential catcinogenic function of DDX5","volume":"23","author":"Wu","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.cellsig.2022.110537_bb0240","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1016\/j.bbrc.2018.08.063","article-title":"DDX5 promotes hepatocellular carcinoma tumorigenesis via Akt signaling pathway","volume":"503","author":"Xue","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cellsig.2022.110537_bb0245","doi-asserted-by":"crossref","first-page":"42876","DOI":"10.1038\/srep42876","article-title":"DDX5 promotes gastric cancer cell proliferation in vitro and in vivo through mTOR signaling pathway","volume":"7","author":"Du","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellsig.2022.110537_bb0250","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1038\/onc.2015.42","article-title":"The DEAD box protein p68: a crucial regulator of AKT\/FOXO3a signaling axis in oncogenesis","volume":"34","author":"Sarkar","year":"2015","journal-title":"Oncogene."},{"key":"10.1016\/j.cellsig.2022.110537_bb0255","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.molcel.2007.03.003","article-title":"PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase","volume":"25","author":"Sancak","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cellsig.2022.110537_bb0260","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S1097-2765(03)00220-X","article-title":"Insulin activation of Rheb, a mediator of mTOR\/S6K\/4E-BP signaling, is inhibited by TSC1 and 2","volume":"11","author":"Garami","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cellsig.2022.110537_bb0265","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cell.2005.02.031","article-title":"Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis","volume":"121","author":"Ma","year":"2005","journal-title":"Cell."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656822002996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656822002996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:07:46Z","timestamp":1760267266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656822002996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":53,"alternative-id":["S0898656822002996"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2022.110537","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The indispensable role of the RNA helicase DDX5 in tumorigenesis induced by the myeloproliferative neoplasm-associated JAK2V617F mutant","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2022.110537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110537"}}